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Abstract
Background: So far only single cases with short follow-up have been reported on the use of intravitreal anti-VEGF
for traumatic choroidal neovascularizations (CNV). This paper reports a large case series of patients with CNV
secondary to choroidal rupture after ocular trauma receiving intravitreal anti-VEGF (vascular endothelial growth
factor) injections.
Methods: Fifty-four patients with unilateral choroidal rupture after ocular trauma diagnosed between 2000 and
2016 were retrospectively evaluated. Eleven patients with CNV secondary to choroidal rupture were identified. Five
eyes with traumatic secondary CNV were treated with anti-VEGF and were systematically analysed. The other 4
patients with inactive CNV underwent watchful observation.
Results: Four men and one woman with a mean age of 29 years (SD 12.4; range 19–45) had intravitreal anti-VEGF
therapy for traumatic CNV. Another 4 patients with a mean age of 37 years (SD 6.6; range 31–46) presented with
inactive CNV and did not receive specific treatment. In all 9 cases the mean interval between the ocular trauma and
the diagnosis of CNV was 5.7 months (SD 4.75; range 2–12). In the treatment group per eye 4.2 injections (SD 3.2;
range 1–8) were given on average. Four eyes were treated with bevacizumab and one eye with ranibizumab.
Regression of CNV was noted in all eyes. In 4 eyes visual acuity (VA) improved, one eye kept stable visual acuity.
Conclusions: Here, we present the up to now largest case series of traumatic CNV membranes treated with anti-
VEGF injections with a mean follow-up period of 5 years. Intravitreal anti-VEGF therapy seems to be safe and
effective for secondary CNV after choroidal rupture. Compared to exudative age-related macular degeneration
fewer injections are needed to control the disease.
Trial registration: Retrospective registration with local ethics committee on 21 March 2019. Trial registration
number is 19-1368-104.
Keywords: Secondary choroidal neovascularization, Choroidal rupture, Intravitreal anti-VEGF (vascular endothelial
growth factor) treatment
Introduction
Traumatic choroidal neovascularization (CNV) occurs in
patients with choroidal rupture following severe ocular
injuries [1]. Compared to CNV in age-related macular
degeneration (AMD) the course of traumatic neovascu-
lar membranes is relatively benign [1]. As choroidal neo-
vascularizations are a consistent part of the ocular repair
mechanism they usually regress spontaneously as part of
the healing process [2, 3]. The formation of persistent
CNV with substantial loss of central vision happens in
5-25% of eyes with choroidal ruptures [1, 3]. In the early
phase (within 6 months of the injury) the CNV develop-
ment is explained by an exuberant repair reaction or just
persistence of the normal reparative neovascular tissue
[1]. Late CNV formation (after one year of the injury)
could either be caused by awakening of an old dormant
CNV or more likely by a new CNV in an area of local
weakness [1]. In earlier days selected case of traumatic
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CNV were treated by photodynamic therapy (PDT) [4, 5],
laser photocoagulation [6] or submacular surgery [7].
After the introduction of intravitreal anti-VEGF (vascular
endothelial growth factor) as therapy for exudative AMD
some reports of antiangiogenic injections for CNV of
other causes than AMD [8–10] and in younger popula-
tions [11] have been published. So far no larger only single
case reports have been published on intravitreal injections
for traumatic CNV [12–14]. Thus, it is important to col-
lect data about the use of intravitreal anti-VEGF agents in
individuals with this condition.
Methods
We identified 54 cases of choroidal rupture after ocular
trauma, which were diagnosed between 2000 and 2016
at a large tertiary university eye hospital. Eleven patients
with CNV secondary to choroidal rupture were identi-
fied and further evaluated. We divided the study popula-
tion in two different groups. The first group (n = 5)
included patients with active CNV lesion at initial pres-
entation, that received intravitreal anti-VEGF injections.
The second group (n = 4) consisted of eyes with inactive
CNV at first presentation which did not receive specific
treatment. The two remaining patients were excluded
because of different treatment strategies (vitrectomy,
PDT). The patients' medical records were retrospectively
analysed. The following parameters were assessed: age,
sex, type of injury, interval between trauma and CNV
formation, treatment modalities and rate of recurrence.
For anonymization the patients were grouped into differ-
ent age groups (18-25 years, 26 -30 years, 31 - 40 years,
41 - 50 years.) The baseline examination included meas-
urement of best corrected visual acuity (BCVA), slit
lamp examination, ophthalmoscopy and retinal imaging.
Diagnosis of CNV secondary to choroidal rupture was made
clinically by at least two retina specialists and was confirmed
by multimodal imaging of the posterior segment. ) Fundus
fluorescein angiography (FFA) was achieved with Spectralis®
(Heidelberg Engineering, Heidelberg, Germany). On the
basis of the FFA images the greatest linear dimension (GLD)
of the lesion was calculated and the type, activity and loca-
tion of the CNV was analysed (subfoveal: within the foveal
avascular zone (FAZ), juxtafoveal: distance from FAZ ≤ 200
μm, extrafoveal: distance from FAZ > 200 μm). The decision
of the treatment modality was made by at least two inde-
pendent ophthalmologists and was based on the activity of
the CNV lesion verified by leakage on FFA images. For the
patients that underwent no specific CNV treatment no fur-
ther optical coherence tomography (OCT) scans were per-
formed. For the patients that underwent anti-VEGF
treatment retinal imaging included also optical coherence
tomography (OCT) at baseline and on all follow-up visits
with a central 6-line radial OCT. The central foveal thickness
(CFT) was calculated and the existence of intra- or subretinal
fluid was noted. The definition of recurrence was reappear-
ing activity either seen by leakage on FFA images or fluid on
OCT scans at least three months after the last injection. The
patients in the treatment group received at least one anti-
VEGF injection of either bevacizumab (1.25 mg/0.05 ml) or
ranibizumab (0.5 mg/0.05 ml). There was no standardised
treatment protocol. In every case the count, frequency and
substance of anti-VEGF injections was chosen individually.
The follow-up examination included Snellen's charts visual
acuity, slit-lamp examination, funduscopy and retinal im-
aging. A conversion of the visual acuity equivalents attained
using Snellen's charts to logMAR values was performed for
statistical evaluation. The statistical investigation was
achieved by using SPSS 23.0 (IBM, Chicago, USA). Categor-
ical variables are listed as frequency counts and percentages.
Continuous values are displayed as mean ± standard devi-
ation and range (min-max); Mean values were compared
using Student’s t-test. A p-value <0.05 was considered statis-
tically significant.
Results
Demographic and clinical data
Overall, 54 patients were diagnosed with choroidal rupture
after ocular trauma between 2000 and 2016. Eleven (20%)
of these patients developed secondary CNV. One patient in
2001 was treated with focal laser photocoagulation and
PDT before the introduction of intravitreal anti-VEGF. An-
other patient underwent pars-plana-vitrectomy for CNV-
related vitreous haemorrhage. Of the 9 remaining cases, 5
eyes diagnosed between 2009 and 2016 with secondary
traumatic CNV received intravitreal antiangiogenic treat-
ment. In the 4 other eyes no specific medical treatment was
recommended because of inactivity of the lesion at initial
presentation. Overall 6 (67%) right eyes and 3 (33%) left eye
were assessed. The study population involved 6 (67%) men
and 3 women (33%). The mean age was 32 years (SD 10.3;
range 19-46). Eight patients had a history of blunt trauma
with one case of multiple facial fractures. The ninth patient
presented with choroidal rupture after a penetrating eye in-
jury with an intraocular foreign body. In every case the
CNV development occurred within the early phase of one
year after injury. The mean interval between the ocular
trauma and the diagnosis of CNV was 5.7 months (SD 4.75;
range 2-12). At baseline three patients reported decreased
central vision with an average duration of symptoms of 10
weeks (SD 12; range 2-24). Six patients were diagnosed with
CNV during posttraumatic routine follow-up examination.
Table 1 summarizes the demographic and clinical data of
the treatment group and the group without therapy.
Morphologic and anatomical results
At the initial diagnosis all 9 eyes presented with a classic
CNV lesion. In 4 eyes the CNV was located extrafoveally
(44%), three CNV membranes were in the subfoveal
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region (33%) and 2 patients showed juxtafoveal location
(22%). Four eyes (44%) with an inactive and scarred
CNV lesion at initial presentation underwent watchful
observation and did not receive specific medical treat-
ment. Five eyes (56%) showed manifest CNV activity de-
tected by apparent leakage on FFA images and were
treated with intravitreal anti-VEGF injections. In these
eyes with CNV the baseline OCT scan showed a mean
CFT of 645 μm (SD 359, range 329-1240). After comple-
tion of anti-VEGF-therapy an average CFT of 403 μm
(SD 145, range 214-586) was measured at the last visit.
This reduction of CFT after anti-VEGF treatment was
not statistically significant (p= 0.089). FFA was per-
formed in all 9 eyes and showed a mean GLD of the
neovascular membrane of 1296 μm (SD 717 μm, range
451-2725). Details about the CNV morphology in the
treatment group as well are listed in Table 2. Figure 1
shows fundus and FFA images of a 19-year-old male
with traumatic CNV in the left eye. The OCT scans of a
23-year-old man with traumatic CNV in the right eye
before treatment and 4 weeks after the last injection are
presented in Fig. 2.
Treatment characteristics and recurrence rates
The 5 patients with an active CNV lesion received intra-
vitreal antiangiogenic treatment as primary treatment for
CNV. On average, 4.2 injections (SD 3.1, range 1-8) were
given per eye. Four eyes were treated with bevacizumab, 1
eye with ranibizumab. The decision about the injection
scheme was made individually and was dependent on the
size and activity of the lesion. In two (40%) eyes, which re-
ceived a single anti-VEGF load at the beginning, this single
injection was sufficient to control the disease. The other 3
(60%) eyes were treated with an upload of three monthly
injections. After a three month treatment pause 2 of these
patients needed another 2 or 3 injections to control the
CNV activity over a period of 3 to 6 months. In one of
these patients recurrence occurred after a six-month treat-
ment pause and was controlled by a single re-injection.
The third patients with an initial upload of three injections
had a two month treatment pause and another five injec-
tions afterwards over a period of half a year.
Functional outcome in the treatment group
Before the anti-VEGF treatment the mean logMAR
BCVA in the treatment group was 0.80 (SD 0.32, range
0.4-1.3), which equates to a decimal visual acuity (VA)
of 0.16. The logMAR BCVA in the cases without further
therapy was 1.2 (SD 0.35, range 0.7-1.5) equivalent to a
decimal VA of 0.06. As expected the group of patients
with an inactive, scared CNV had a worse VA at baseline
than the eyes of the treatment group. After the anti-
VEGF therapy an average logMAR BCVA of 0.42 (SD
0.26, range 0.1-0.8) was assessed in the treatment group,
which equates to a decimal VA of 0.4. Every CNV
responded well to anti-VEGF treatment and all eyes
Table 1 Clinical data of patients with traumatic choroidal neovascularization (CNV) treated with anti-VEGF [Group 1] and patient
without CNV treatment [Group 2]
Patients with traumatic CNV Group 1 (intravitreal anti-VEGF) Group 2 (no treatment) Both groups
No. of cases 5 4 9
Right eyes 4 (80%) 2 (50%) 6 (67%)
Age (years) 29 ± 12.4 37 ± 6.6 32 ± 10.3
Sex (men) 4 (80%) 2 (50%) 6 (67%)
Time between trauma and CNV (months) 6.0 ± 4.6 5.3 ± 5.9 5.7 ± 4.75
GLD of the CNV (μm) 1345 ± 865 1215 ± 535 1296 ± 717
Initial logMAR BCVA 0.80 ± 0.32 1.2 ± 0.35 0.98 ± 0.38
Final logMAR BCVA 0.42 ± 0.26 1.1 ± 0.35 0.66 ± 0.43
Follow-up (months) 62 ± 32 82 ± 66 69 ± 44
BCVA Best corrected visual acuity, GLD Greatest linear diameter, CFT Central foveal thickness
Data present mean ± SD or absolute number (percentage)
Table 2 Morphologic characteristics of 5 traumatic choroidal neovascularizations (CNV) treated with intravitreal anti-VEGF-injections
No. Location of choroidal rupture CNV type CNV location CNV activity GLD (μm) Initial CFT (μm) Final CFT (μm)
1 ~ 1 PD above optic disc classic extrafoveal active 451 568 434
2 ~ 1 PD under optic disc classic extrafoveal active 1124 1240 586
3 ~ 1 PD above optic disc classic extrafoveal active 890 329 307
4 ~ 1 PD temporal optic disc classic subfoveal active 1535 410 214
5 ~ 1 PD temporal optic disc classic subfoveal active 2725 678 475
GLD Greatest linear diameter, FFA Fundus fluorescein angiography, CFT Central foveal thickness, VEGF Vascular endothelial growth factor
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presented with improved (n = 4, 80%) or stable VA (n =
1, 20%) after the last anti-VEGF injection. The mean
change of BCVA was + 3.8 lines (SD 4.8; range 0-12).
Nevertheless, the difference between baseline VA and
final VA was statistically not significant (p = 0.152). In
the group without treatment the mean logMAR BCVA
was 1.1 (SD 0.35, range 0.7 -1.4) at the last follow-up ap-
pointment. There was no significant change between
baseline and follow-up VA in this group (p = 0.939).
The follow-up period was 62 (SD 32; range 17 - 102)
months in the treatment group and 82 months (SD 66;
range 6 - 120) in the group without therapy. Table 3
gives a detailed overview of the clinical parameters of
the treatment group.
Discussion
Traumatic choroidal ruptures are seen in 5-10 % of pa-
tients with blunt ocular injuries [15, 16]. The growth of
a secondary trauma-related CNV is a common compli-
cation in such eyes [1]. In our study population 20 % of
all patients with traumatic choroidal rupture developed
a CNV, which is in agreement with other publications
[3, 15]. In line with other authors [15], we also had a
young study population developing traumatic CNV with
an average age of 32 years. Consistent with our data
most patients with traumatic chorioretinopathies are
male (up to 90%) [15].
Not every traumatic CNV needs to be treated [15]. The
development of fibrovascular tissue and neovascularisation
Fig. 1 Traumatic CNV in a 19-year-old male. Colour image and fundus fluorescein angiography (FFA) of a 19-year-old man with traumatic
choroidal neovascularization (CNV) in the left eye. Arcuate choroidal rupture can be seen under-crossing the vessels above the optic disc. The
greyish CNV with ambient subretinal bleeding, located in the papillomacular region, shows significant leakage on FFA.
Fig. 2 Regression of traumatic CNV in a 23-year-old male treated with anti-VEGF. Optical coherence tomography images of the right eye of a 19-
year-old man with traumatic choroidal neovascularization (CNV) a) before treatment and b) four weeks after the last Bevacizumab injection
showing regression of CNV. BCVA = best corrected visual acuity on day of retinal imaging
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is part of the expected healing process and some CNV
membranes can undergo watchful observation while
regressing [2, 3, 15]. This is consistent with our report of
4 of 11 CNV membranes (36 %) that did not receive fur-
ther ophthalmic treatment because of inactivity and scar-
ring of the lesion at initial presentation. However, in cases
of symptomatic CNV development and activity of the le-
sion verified by FFA imaging prompt treatment is indi-
cated. Before the anti-VEGF aera secondary CNV
membranes were treated with laser photocoagulation [6],
photodynamic therapy [4, 5] or vitreoretinal surgery [7].
There is nowadays consensus that secondary CNV mem-
branes should receive intravitreal anti-VEGF treatment as
first-line-therapy [17].
To our knowledge, only single case reports have been
published so far on intravitreal anti-VEGF therapy for
traumatic CNV in the past [12–14]. In these cases one in-
jection of either ranibizumab [12] or bevacizumab [13, 14]
was administered. However, the follow-up period with a
range of 6 to 12 months was quite short compared to our
study. This fact could explain the low number of injec-
tions given in these individual cases. In our series one case
of late recurrence after a six months treatment pause oc-
curred, which emphasizes the need of a thoroughly and
adequate long follow-up on these patients. There are also
larger retrospective studies with up to 21 cases of intravit-
real antiangiogenic treatment of neovascular membranes
in younger patients (< 50 years of age) and from other
causes than AMD [8–10]. So far, the MINERVA study is
the largest prospective phase III trial to evaluate ranibizu-
mab for treatment of CNV of uncommon cause. In this
study the group of choroidal neovascularization of miscel-
laneous etiology included 6 patients with choroidal rup-
ture and 1 with posttraumatic etiology, but no separate
evaluation of the traumatic CNV group is available [18].
In our patient population with secondary traumatic
CNV intravitreal anti-VEGF therapy was effective in the
treatment group in respect of functional and anatomical
outcome. In every case a good response to anti-VEGF
therapy was noted by CNV regression documented on
OCT and FFA imaging. In all treated eyes the CFT was
reduced compared to the baseline examination. Every
eye showed an improved (n = 4) or stable (n = 1) BCVA
with an average gain of 3.8 BCVA lines. Although the
improvement in BCVA (p = 0.152) and reduction of
CFT (p = 0.089) was not statistically significant due to
the low sample size, we consider the difference of mean
values of BVCA and CFT between baseline and final visit
as clinically relevant. As expected in the group without
anti-VEGF treatment no significant change was noted
between baseline and follow-up VA (p = 0.939).
Overall, we conclude that in younger individuals with
secondary traumatic CNV the response to intravitreal
antiangiogenic treatment seems to be more favourable
than in older patients with wet AMD [19]. Congruent
with our data, the average count of anti-VEGF injections
required to control the activity of the disease is lower
compared to patients with AMD-related CNV [18]. Al-
though good results have been achieved with intravitreal
antiangiogenic drugs, the lack of long-term data regard-
ing safety and systemic side effects in young individuals
has to be emphasized. However, in our study population
no serious ocular or systemic side effects were recorded.
Conclusions
We present the up to now largest retrospective case series
with a systematic review of patients with secondary trau-
matic CNV receiving intravitreal anti-VEGF agents with a
mean follow-up of five years. The limitations of our study
are its retrospective design, the low sample size, the lack
of a standard protocol (different injection regimes and
anti-VEGF agents) and the monocentric character. The
sample size is compared to other single case reports quite
good and every case was well documented including ret-
inal imaging. Further clinical trials with a prospective and
randomized character are unlikely to be published with
refer to the rarity of this condition.
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